Stockreport

Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis [Yahoo! Finance]

Eupraxia Pharmaceuticals Inc.  (EPRX) 
PDF Early low-dose cohorts showing meaningful improvement in patient symptoms and biological evidence of disease Trial expansion allows more patients to be treated at hig [Read more]